Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
OBJECTIVE
To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics.


METHODS
Case reports.


METHODS
University hospital endocrinological outpatient clinic.


METHODS
A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma.


METHODS
Treatment with vaginal cabergoline (0.5 mg two and five times a week).


METHODS
The serum PRL levels and side effects were assessed before and during treatment.


RESULTS
A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patients with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported.


CONCLUSIONS
Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.
Motta
T
T
Prima Clinica Ostetrica e Ginecologica, Università di Milano, Italy.
de Vincentiis
S
S
Marchini
M
M
Colombo
N
N
D'Alberton
A
A
D000328:Adult; D001971:Bromocriptine / Q000009:adverse effects; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D014621:Vagina
D018491:Dopamine Agonists; D004873:Ergolines; D001971:Bromocriptine; D000077465:Cabergoline